Sellas Life Sciences Group Inc Stock Price, News & Analysis

SELLAS Life Sciences (NASDAQ: SLS) announced that Dr. Angelos Stergiou, President and CEO, will participate in the J.P. Morgan U.S. Opportunities Forum with 1x1 investor meetings on Wednesday, November 12, 2025 at the Kimpton EPIC Hotel in Miami, Florida.

The company will host one-on-one meetings; investors should register via J.P. Morgan or contact their J.P. Morgan representative for access.

SELLAS Life Sciences (NASDAQ: SLS) will present preclinical in vivo data showing that its selective CDK9 inhibitor SLS009 (tambiciclib) prolonged survival in a T-cell prolymphocytic leukemia (T-PLL) patient-derived xenograft (PDX) model at ESMO Congress 2025 (Oct 17–21, 2025).

In the PDX model, SLS009 monotherapy and SLS009 plus venetoclax yielded median overall survival of 7.4 weeks and 7.9 weeks versus 4.4 weeks for venetoclax alone (statistically significant, p<0.05), with better control of circulating T-PLL cells and acceptable tolerability for the combination.

SELLAS Life Sciences (NASDAQ: SLS), a late-stage biopharmaceutical company, announced a virtual R&D Day scheduled for October 29, 2025, at 10:00 AM ET. The event will focus on acute myeloid leukemia (AML) treatments and feature key opinion leaders alongside company management.

The presentation will highlight two key programs: the Phase 3 REGAL trial of GPS with results expected by year-end, addressing AML patients in complete second remission (CR2), and an update on SLS009, their selective CDK9 inhibitor. The company will discuss recently reported Phase 2 data for SLS009 and plans for a frontline AML study set to begin in Q1 2026.

SELLAS Life Sciences (NASDAQ: SLS), a late-stage clinical biopharmaceutical company, announced the exercise of warrants from a January 2025 issuance, generating $23.6 million in gross proceeds. The transaction involves the purchase of 19,685,040 shares of common stock.

In exchange for this immediate exercise, the institutional investor will receive new unregistered warrants to purchase an equal number of shares at an exercise price of $1.88. These new warrants will be exercisable immediately with a 5.5-year expiration period. The transaction is expected to close around September 12, 2025.

SELLAS Life Sciences (NASDAQ: SLS) reported Q2 2025 financial results and significant progress in its AML-focused pipeline. The company's Phase 3 REGAL trial of GPS received a positive IDMC recommendation to continue without modification, with final analysis expected by year-end 2025.

Their Phase 2 trial of SLS009 in r/r AML achieved impressive results, with a 44% response rate in AML-MRC patients and median overall survival of 8.9 months, significantly exceeding historical benchmarks. The FDA has recommended advancing SLS009 to first-line AML treatment, with an 80-patient trial expected to begin by Q1 2026.

Financially, SELLAS reported a Q2 2025 net loss of $6.6 million ($0.07 per share), with $25.3 million in cash as of June 30, 2025, plus an additional $4.0 million from warrant exercises in July 2025.

SELLAS Life Sciences (NASDAQ: SLS) announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) for its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML). The IDMC's review supports continuing the trial without modifications, confirming GPS's favorable risk-benefit profile.

The study, which completed enrollment in April 2024 with 126 patients, predominantly recruited from U.S. and European sites (75% of total enrollment). The final analysis, expected by year-end, will be triggered when 80 events (deaths) occur, which will determine GPS's potential effectiveness in AML treatment.

SELLAS Life Sciences (NASDAQ: SLS) announced successful completion of its Phase 2 trial for SLS009 (tambiciclib) in relapsed/refractory acute myeloid leukemia (r/r AML), meeting all primary endpoints. The trial demonstrated an impressive 44% response rate among AML-MR patients and 50% in AML-MR with M4/M5 subtype at the optimal 30mg twice-weekly dose.

Key achievements include median overall survival of 8.9 months in AML-MR patients and 8.8 months in venetoclax-refractory patients, significantly surpassing the historical benchmark of 2.4 months. Following FDA guidance, SELLAS will advance to a randomized 80-patient trial including newly diagnosed first-line AML patients, with enrollment expected to begin by Q1 2026.

SELLAS Life Sciences (NASDAQ: SLS), a late-stage clinical biopharmaceutical company, has appointed Dr. Linghua Wang to its Scientific Advisory Board. Dr. Wang, a tenured Associate Professor at MD Anderson's Department of Genomic Medicine, brings extensive expertise in cancer immunogenomics and computational biology.

Dr. Wang leads the Computational Biology Laboratory at MD Anderson and holds multiple prestigious positions, including Associate Member of The James P. Allison Institute. Her research focuses on understanding tumor ecosystems using advanced technologies like single-cell and spatial omics, AI-driven pathology, and machine learning. With over 100 publications and multiple NIH/NCI grants, her expertise aligns with SELLAS's focus on translational research and precision medicine.

SELLAS Life Sciences (NASDAQ: SLS), a late-stage clinical biopharmaceutical company, announced its upcoming addition to the Russell 3000® and Russell 2000® Indexes, effective June 27, 2025. This inclusion marks a significant milestone for the company, reflecting its progress in pipeline development.

The Russell 3000® Index tracks the top 3,000 U.S. public companies, while the Russell 2000® Index focuses on small-cap stocks representing about 10% of the U.S. equity market capitalization. The company is approaching key milestones, including topline Phase 2 data readout for SLS009 in acute myeloid leukemia (AML) and final analysis of the Phase 3 REGAL trial of GPS in AML.